Intercell AG

euro adhoc: Intercell AG
quarterly or semiannual financial statement / Intercell AG announces Q1 results and update on development programs: Adjuvant IC31TM opens attractive new market opportunity in Flu - All development projects on track - Strong foc

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- quaterly report 14.05.2007 IC31TM - Clinical results emphasize broad and commercial use in vaccine development » Protective profile for IC31TM in Phase I Tuberculosis vaccine trial - strong T-cell immune responses in humans confirming broad pre-clinical data base » Promising pre-clinical data for the use of IC31TM in next generation Flu vaccines - first clinical trials planned for 2007 » Next Milestones - start of a Phase I "proof-of-concept" clinical trial for an IC31TM adjuvanted Flu vaccine and strong focus on a commercial use of IC31TM and further strategic partnerships All development projects on track and within expected timelines » Japanese Encephalitis vaccine - all preparations for expected market launch in the US early 2008 and late 2008 in Europe are on track Regulatory clearance to start a pediatric Phase II clinical trial in India obtained - start of Phase II trial within the next few weeks » Hepatitis C vaccine - Phase II "proof-of-concept" study fully recruited - first data expected by mid 2007 - forward strategies comprise options for mono- and/or combination therapies » Pneumococcus vaccine - preparations for start of Phase I clinical trial on track Nosocomial (hospital-acquired) infections - Building the leading vaccine franchise » Staphylococcus aureus vaccine partnered with Merck & Co. - safe and immunogenic in Phase I clinical trials - Phase II expected to start in 2007 » Pseudomonas vaccine - preparations for start of clinical Phase II/III trials on track » Enterococcus/Klebsiella vaccines - AIP® accelerated to progress into clinical development Strong financial position - Net loss further reduced » EUR 7.1 million net loss for Q1 2007 - down 19.3 percent as compared to Q1 2006 » Increase of aggregate revenues - EUR 1.5 million in Q1 2007 compared to EUR 0.3 million in Q1 2006 » EUR 7.4 million R&D expenses in Q1 2007 - up 8.8 percent as compared to Q1 2006 » Strong cash position with EUR 86.3 million in liquid funds at March 31, 2007 end of announcement euro adhoc 14.05.2007 06:57:42 -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Intercell AG Mag. Katharina Wieser Head of Corporate Communications Tel. +43 1 20620-303 kwieser@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Börsen: Wiener Börse AG / official market

Das könnte Sie auch interessieren: